Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy | Aplastic Anemia & MDS International Foundation Return to top.

Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy

Journal Title: 
Leukemia & Lymphoma
Primary Author: 
Lee S
Author(s): 
Lee S, Desai P, Edirisinghe B, Pianello S, Curcio T, Samuel M, Ritchie EK, Roboz GJ
Original Publication Date: 
Saturday, October 10, 2020
Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Share with addtoany.com.